- Home
- REVG vs KLTOW Comparison
REVG vs KLTOW Comparison
Compare REVG & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVG
- KLTOW
- Stock Information
- Founded
- REVG 2008
- KLTOW N/A
- Country
- REVG United States
- KLTOW United States
- Employees
- REVG N/A
- KLTOW 3
- Industry
- REVG Auto Manufacturing
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REVG Consumer Discretionary
- KLTOW Health Care
- Exchange
- REVG Nasdaq
- KLTOW Nasdaq
- Market Cap
- REVG N/A
- KLTOW N/A
- IPO Year
- REVG 2017
- KLTOW 2022
- Fundamental
- Price
- REVG $38.02
- KLTOW $0.02
- Analyst Decision
- REVG Hold
- KLTOW
- Analyst Count
- REVG 4
- KLTOW 0
- Target Price
- REVG $33.75
- KLTOW N/A
- AVG Volume (30 Days)
- REVG 664.3K
- KLTOW N/A
- Earning Date
- REVG 06-04-2025
- KLTOW N/A
- Dividend Yield
- REVG 0.63%
- KLTOW N/A
- EPS Growth
- REVG N/A
- KLTOW N/A
- EPS
- REVG 1.77
- KLTOW N/A
- Revenue
- REVG $2,319,300,000.00
- KLTOW N/A
- Revenue This Year
- REVG $1.97
- KLTOW N/A
- Revenue Next Year
- REVG $6.51
- KLTOW N/A
- P/E Ratio
- REVG $21.74
- KLTOW N/A
- Revenue Growth
- REVG N/A
- KLTOW N/A
- 52 Week Low
- REVG $21.54
- KLTOW N/A
- 52 Week High
- REVG $36.06
- KLTOW N/A
- Technical
- Relative Strength Index (RSI)
- REVG 73.69
- KLTOW N/A
- Support Level
- REVG $31.57
- KLTOW N/A
- Resistance Level
- REVG $36.06
- KLTOW N/A
- Average True Range (ATR)
- REVG 1.01
- KLTOW 0.00
- MACD
- REVG 0.46
- KLTOW 0.00
- Stochastic Oscillator
- REVG 93.89
- KLTOW 0.00
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.